Table 1 Baseline qualitative characteristics of included studies
Study | NCT ID | Country | Intervention | Control | Population | Primary outcome | Outcomes measureda |
|---|---|---|---|---|---|---|---|
Abraham [26] | ACTRN12616000753459 | Australia | MiniMed 670G | MDI/SAP therapy | Adults and Children | TIR 70–180 mg/dL | Clinical and functional |
ADAPT (Choudhary [27]) | NCT04235504 | France, Germany And UK | MiniMed 670G | MDI therapy | Adults | Change in HbA1c | Clinical and functional |
APCam11 (Tauschmann [28]) | NCT02523131 | USA and UK | Modified FlorenceM | SAP therapy | Adults and children | TIR 70–180 mg/dL | Clinical and functional |
AP@home (Thabit [29]) | NCT01778348 + NCT01961622 | UK, Germany and Austria | FlorenceD2A and FlorenceD2W | SAP therapy | Adults and children | TIR 70–180 mg/dL for adults and TIR 70–145 mg/dL for children and adolescents | Clinical |
Boughton [30] | NCT04025762 | UK and Austria | CamAPS FX | SAP therapy | Adults | TIR 70–180 mg/dL | Clinical |
Brown [31] | NCT03591354 | USA | t:slim X2 with control-IQ | PLGS therapy | Adults | TIR 70–180 mg/dL | Clinical |
Burnside [32] | ACTRN12620000034932 | New Zealand | AndroidAPS 2.8 | SAP | Adults and children | TIR 70–180 mg/dL | Clinical |
NCT02925299 | UK and USA | FlorenceM or CamAPS FX | SAP therapy | Children | Change in HbA1c | Clinical and functional | |
DAN06 (Boughton [34]) | NCT02871089 | UK | FlorenceM/CamAPS FX | MDI therapy | Children and adolescents | AUC for the plasma C-peptide | Clinical |
NCT03563313 | USA | t:slim X2 with Control-IQ | SAP therapy | Adults and children | TIR 70–180 mg/dL | Clinical and functional | |
DCLP4 (Pinsker [36]) | NCT04436796 | USA | Interoperable artificial pancreas system (iAPS) | SAP/PLGS therapy | Adults | TIR 70–180 mg/dL | Clinical and functional |
NCT03844789 | USA | t:slim X2 with control-IQ | SAP/PLGS therapy | Children | TIR 70–180 mg/dL | Clinical and functional | |
DIABELOOP WP7 (Benhamou [38]) | NCT02987556 | France | Diabeloop Generation 1 (DBLG1) | SAP therapy | Adults | TIR 70–180 mg/dL | Clinical and functional |
iDCL (Kovatchev [39]) | NCT02985866 | USA | Control-IQ | SAP therapy | Adults | Time below 70 mg/dL and above 180 mg/dL | Clinical |
Garg [40] | NCT02748018 | USA and Canada | MiniMed 670G hybrid closed loop | CSII | Children, adolescents and adults | Group 1: change in HbA1c Group 2: reducing %TBR < 70 mg/dL | Clinical and functional |
Matejko [7] | NCT04616391 | Poland | MiniMed 780G | MDI therapy | Adults | TIR 70–180 mg/dL | Clinical and functional |
McAuley [41] | ACTRN12617000520336 | Australia | MiniMed 670G | MDI/SAP therapy | Adults | TIR 70–180 mg/dL | Clinical and functional |
ORACL (McAuley [42]) | ACTRN126190000516190 | Australia | MiniMed 670G | SAP therapy | Adults | TIR 70–180 mg/dL | Clinical and functional |
PEDAP trial (Wadwa) [43]) | NCT04796779 | USA | T:slim X2 with Control-IQ | MDI/SAP therapy | Children | TIR 70–180 mg/dL | Clinical |
Reiss [44] | NCT03428932 | USA | MiniMed 670G | MDI/SAP therapy | Children | Metrics of gray matter | Clinical and functional |
Russell [11] | NCT04200313 | USA | iLet device | PLGS/SAP/MDI therapy | Adults and children | Change in HbA1c | Clinical |
Ware [45] | NCT03784027 | Austria, Germany, Luxembourg and UK | CamAPS FX | SAP therapy | Children | TIR 70–180 mg/dL | Clinical |